Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 24439864)

Published in Int J Cardiol on January 11, 2014

Authors

Ting-Hsing Chao1, Shih-Ya Tseng2, I-Chih Chen3, Yi-Shan Tsai4, Yao-Yi Huang5, Ping-Yen Liu6, Horng-Yih Ou6, Yi-Heng Li6, Hua-Lin Wu7, Chung-Lung Cho2, Liang-Miin Tsai6, Jyh-Hong Chen6

Author Affiliations

1: Department of Internal Medicine, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan. Electronic address: chaotinghsing@yahoo.com.tw.
2: Department of Biological Science, National Sun Yat-Sen University, Kaohsiung, Taiwan.
3: Department of Internal Medicine, Tainan Municipal Hospital, Tainan, Taiwan.
4: Department of Radiology, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan.
5: Department of Emergency Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
6: Department of Internal Medicine, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan.
7: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Associated clinical trials:

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease | NCT02194686

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease | NCT02174939